Navigation Links
One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
Date:10/27/2008

New Findings Also Demonstrate Treatment Results in Improvements in Physical

Function and Health-Related Quality of Life

SAN FRANCISCO, Oct. 27 /PRNewswire/ -- More than half of patients receiving every four week subcutaneous injections of golimumab (CNTO 148) 50 mg and 100 mg, an investigational therapy, experienced sustained improvements in the joint and skin symptoms of active psoriatic arthritis through six months with results sustained through one year. Golimumab-treated patients also experienced improvements in health-related quality of life (HRQOL) in the placebo-controlled portion of the study (through week 24) along with the substantial improvements in physical function and arthritis and psoriasis components of the disease. These findings were presented at the American College of Rheumatology (ACR) annual meeting.

"These results demonstrate long-term efficacy of every four week dosing with golimumab in improving physical symptoms and functional ability as well as improving quality of life," said Arthur Kavanaugh, M.D., Professor of Medicine, University of California, San Diego, School of Medicine, and lead study investigator. "The sustained effects of golimumab as demonstrated in these study findings are encouraging for both the physicians treating this condition and for the many patients living with this potentially debilitating disease."

In the study, Golimumab - A Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal Antibody (GO-REVEAL), 52 percent and 61 percent of patients receiving golimumab 50 mg and 100 mg, respectively, achieved at least 20 percent improvement in arthritis signs and symptoms as measured by American College of Rheumatology (ACR 20) response compared with 12 percent of patients receiving placebo (P < 0.001) at week 24. Through one year, 78 percent of patients continuing in the golimumab 50 mg group and 74 percent of patients contin
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. In-Room Computers and Wall-Mounted Proximity Systems Computer WorkStations Deliver Increased Efficiency; Improved Patient Care
5. Finesse Solutions Launches Improved E-Store for Sensors and Transmitters
6. Kelly Osbourne and International Health Groups Call for Improved Education on Choices and Usage of Contraception
7. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
8. Improved culture system for hepatitis C virus infection
9. Pharmacy Students Taught Improved Medication Adherence and Holistic Health Services Through Program Incorporating InforMedixs Med-eXpert(TM) System
10. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
11. China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Companys Cactus Cattle Feed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Based on the revenues gained from surgical ... dominated by four major players contributing to approximately ... include GE Healthcare (U.K.), Siemens AG (Germany), Philips ... Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , The ... to its strong product portfolio, which includes its ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
... Sept. 5 Forest Laboratories, Inc.,(NYSE: FRX ) ... the U.S. Court,of Appeals for the Federal Circuit has ... Court for the District of Delaware which determined that,the ... valid and upheld the injunction preventing Ivax/Teva,s proposed generic,product ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) today announced ... Barocycler NEP2320, a patent-pending, lightweight,compressed air driven pressure ... it has been issued a CB Scheme Test ... been found in,compliance with the IEC 61010-1 international ...
... VICTORIA, BC, Sept. 5 /PRNewswire/ - ... data management software solutions for life ... joined the Affymetrix,GeneChip-compatible(TM) Applications Program, and ... with the Affymetrix, Inc. (Nasdaq:,AFFX) GeneChip(R) ...
Cached Biology Technology:Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision 2Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 2Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 3Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 4GenoLogics' Geneus Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform 2GenoLogics' Geneus Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform 3
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ... the condition and the best ways to treat it. ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... Hollywood, FL (December 12, 2013) A new study shows ... develop depression. The data were presented today at the American ... chronic disorder with a devastating impact on the quality of ... the disorder. The underlying causes of the disorder remain something ...
... December 12, 2013 The critical enzyme beta-secretase1 (BACE1) is ... (AD). Scientists have now found increased levels of BACE1 in ... is important for conversion of mild cognitive impairment to AD ... are published in the January issue of The American ...
... to fix sleep disturbances in mice with traumatic brain injuries ... of thousands of people who have long-term and debilitating sleep ... found helpful was giving the mice something all humans produce ... chain amino acids. "If further research confirms what this ...
Cached Biology News:Peripheral immune system may regulate vulnerability to depression 2Enzyme BACE1 may be important in predicting onset of Alzheimer disease 2Dietary amino acids improve sleep problems in mice with traumatic brain injury 2Dietary amino acids improve sleep problems in mice with traumatic brain injury 3
Concentration: 1mg/ml. Antigen: Propidium Iodide ...
... plastic feeding tubes for rodent oral gavage ... risk of perforation and trauma. Plus they ... cleaning and the risk of cross-contamination. ... 20ga Length: ...
Adult Bovine Serum US Origin...
... the 9, 10, 12, and 13 positions. It ... for the quantification of 13(S)-HODE by GC- or ... linoleic acid with plant and mammalian lipoxygenases. It ... tumor cells to the endothelium at concentrations around ...
Biology Products: